These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24966857)

  • 21. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inoculation of the
    Soto M; Ramírez L; Solana JC; Cook ECL; Hernández-García E; Requena JM; Iborra S
    Microorganisms; 2021 Feb; 9(2):. PubMed ID: 33673117
    [No Abstract]   [Full Text] [Related]  

  • 27. Characterization of cross-protection by genetically modified live-attenuated Leishmania donovani parasites against Leishmania mexicana.
    Dey R; Natarajan G; Bhattacharya P; Cummings H; Dagur PK; Terrazas C; Selvapandiyan A; McCoy JP; Duncan R; Satoskar AR; Nakhasi HL
    J Immunol; 2014 Oct; 193(7):3513-27. PubMed ID: 25156362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live Attenuated
    Banerjee A; Bhattacharya P; Dagur PK; Karmakar S; Ismail N; Joshi AB; Akue AD; KuKuruga M; McCoy JP; Dey R; Nakhasi HL
    J Immunol; 2018 Jan; 200(1):163-176. PubMed ID: 29187586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic role of B cells and antibodies in murine Leishmania amazonensis infection.
    Wanasen N; Xin L; Soong L
    Int J Parasitol; 2008 Mar; 38(3-4):417-29. PubMed ID: 17959178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
    Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
    Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malaria-Cutaneous Leishmaniasis Co-infection: Influence on Disease Outcomes and Immune Response.
    Pinna RA; Silva-Dos-Santos D; Perce-da-Silva DS; Oliveira-Ferreira J; Villa-Verde DM; De Luca PM; Banic DM
    Front Microbiol; 2016; 7():982. PubMed ID: 27446022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
    Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
    Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.
    Costa LE; Chávez-Fumagalli MA; Martins VT; Duarte MC; Lage DP; Lima MI; Pereira NC; Soto M; Tavares CA; Goulart LR; Coelho EA
    Parasitology; 2015 Sep; 142(10):1335-47. PubMed ID: 26099574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.
    Chamakh-Ayari R; Bras-Gonçalves R; Bahi-Jaber N; Petitdidier E; Markikou-Ouni W; Aoun K; Moreno J; Carrillo E; Salotra P; Kaushal H; Negi NS; Arevalo J; Falconi-Agapito F; Privat A; Cruz M; Pagniez J; Papierok GM; Rhouma FB; Torres P; Lemesre JL; Chenik M; Meddeb-Garnaoui A
    PLoS One; 2014; 9(5):e92708. PubMed ID: 24786587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
    Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
    Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.
    Germanó MJ; Mackern-Oberti JP; Vitório JG; Duarte MC; Pimenta DC; Sanchez MV; Bruna FA; Lozano ES; Fernandes AP; Cargnelutti DE
    Front Immunol; 2022; 13():825007. PubMed ID: 35634280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
    Sharma A; Madhubala R
    J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.